Nonalcoholic fatty liver disease (NAFLD) is estimated to afflict approximately 1 billion
individuals worldwide. In a subset of NAFLD patients, who have the progressive form of …

The correct identification of patients at increased risk of non-alcoholic steatohepatitis
(NASH) and advanced fibrosis is a critical step in the assessment of non-alcoholic fatty liver …

Since the publication of the guidelines for the assessment and management of non alcoholic
fatty liver disease (NAFLD) by the Asia–Pacific Working Party on NAFLD in 2007, 1 our …

Chronic liver disease (CLD) is associated with approximately two million annual deaths
worldwide and is an enormous health burden.[1, 2] The majority of liver-related outcomes …

Non-alcoholic fatty liver disease (NAFLD) affects one in every three subjects in the
occidental world. The vast majority will not progress, but a relevant minority will develop liver …

Background Non‐alcoholic fatty liver disease (NAFLD) affects 15–40% of the general
population. Some patients have non‐alcoholic steatohepatitis (NASH) and progressive …

Background Patients with chronic gastrointestinal (GI) disease such as inflammatory bowel
disease (IBD), irritable bowel syndrome (IBS), celiac disease, gastroesophageal reflux …

Objectives: To compare the long-term benefit of gastric bypass [Roux-en-Y gastric bypass
(RYGB)] versus adjustable gastric banding (AGB) on nonalcoholic fatty liver disease …

Nonalcoholic fatty liver disease (NAFLD) is quickly becoming one of the most prominent
causes of liver disease worldwide. The increasing incidence of NAFLD is tied to the obesity …

Non-alcoholic fatty liver disease (NAFLD) is a severe liver disease that is increasing in
prevalence with the worldwide epidemic of obesity and its related insulin-resistance state. A …